BioServe and NGC Medical SpA announced the opening of BioServe-Europe. Based in Milan, Italy BioServe-Europe provides the European life science research industry with a comprehensive range of molecular services, including the processing of new personal genetic tests, high-throughput genotyping, and DNA and RNA extractions. In addition, BioServe-Europe distributes biospecimens from its Global BioRepository and biobank partner network, as well as samples sourced from within the EU.
"The combination of cutting edge genomic services and high-quality biosamples has proven to be a powerful offering for the scientific community in North America. Our recent foray in the EU market, working with NGC Medical, has revealed a similar strong demand for these unique services," said Rama Modali, President, BioServe.
Working with BioServe-Europe, many European scientists will for the first time have access to a single source of biosamples covering most major diseases and comprehensive analytical services to unlock and correlate sample information for their research. These complementary services are crucial to furthering the understanding of disease and the development of new research discoveries and therapies.
Modali added, "The EU market is also quickly adopting new in-vitro diagnostic tests as part of a move to a personalized medicine regime. BioServe-Europe's genomic services have the ability to a key component in the processing and validation of these tests' results."
In April of this year, BioServe began its collaboration with NGC Medical, providing them with a full complement of CLIA-certified personalized genomics services, including DNA extraction, QC DNA, and control DNA for NutriGeneCodeTM validation. NutriGeneCodeTM is a simple, non-invasive saliva test able to identify 50 of the most significant Single Nucleotide Mutations (SNPs) involved in cellular aging and consequent body response, such as lipid and carbohydrate metabolism, hypertension, inflammation, oxidation and detoxification reactions and DNA repair.